While the FDA has granted an accelerated approval for atezolizumab, a monoclonal antibody drug targeting PD-L1, plus chemotherapy for the treatment of TNBC14, the potential application of immune therapies for patients with luminal breast cancer remains largely unknown. This evidence concerns the gene CD274 and breast cancer.